An update on current and future treatment options for chondrosarcoma

ASIA unversity > 醫學暨健康學院 > 醫學檢驗暨生物技術學系 > 期刊論文 > Item 310904400/112731

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://asiair.asia.edu.tw/ir/handle/310904400/112731

题名:	An update on current and future treatment options for chondrosarcoma
作者:	MacDo, Iona J;MacDonald, Iona J;Li, Chih-Yang;Lin, Chih-Yang;Kuo, Shu-Jui;Kuo, Shu-Jui;Su, Chen-Ming;Su, Chen-Ming;湯智昕;Chih-Hsin, Tang
贡献者:	醫學檢驗暨生物技術學系
关键词:	Chondrosarcoma;PDGFR;cytogenetics;herbal medicines;treatment.
日期:	2019-09
上传时间:	2020-08-27 06:31:26 (UTC+0)
出版者:	亞洲大學
摘要:	Introduction: Human chondrosarcomas (CS; a malignant cartilage-forming bone tumor) respond poorly to chemotherapy and radiation treatment, resulting in high morbidity and mortality rates. Expanded treatment options are urgently needed. Areas covered: This article updates our 2014 review, in which we evaluated the CS treatments available at that time and potential treatment options under investigation. Since then, advances in research findings, particularly from Chinese herbal medicines, may be bringing us closer to more effective therapies for CS. In particular, promising findings have been reported from research targeting platelet-derived growth factor receptor. Expert opinion: Few treatment options exist for CS; chemotherapy is not even an option for unresectable disease, in which 5-year survival rates are just 2%. New information about the multitude of genes and signaling pathways that encourage CS growth, invasion and metastasis are clarifying how certain signaling pathways and plant-derived active compounds, especially molecularly-targeted therapies that inhibit the PDGF receptor, interfering with these biological processes. This review summarizes discoveries from the last 5 years and discusses how these findings are fueling ongoing work into effectively dealing with the disease process and improving the treatment of CS.
關聯:	Expert Review of Anticancer Therapy
显示于类别:	[醫學檢驗暨生物技術學系] 期刊論文

文件中的档案:

档案	描述	大小	格式	浏览次数
index.html		0Kb	HTML	170	检视/开启

检视Licence

在ASIAIR中所有的数据项都受到原著作权保护.

数据加载中.....